Deleobuvir
Modify Date: 2025-09-11 08:00:08
Deleobuvir structure
|
Common Name | Deleobuvir | ||
|---|---|---|---|---|
| CAS Number | 863884-77-9 | Molecular Weight | 653.568 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 851.4±65.0 °C at 760 mmHg | |
| Molecular Formula | C34H33BrN6O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 468.7±34.3 °C | |
Use of DeleobuvirDeleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients. HCV Infection Phase 3 Clinical |
| Name | Deleobuvir |
|---|---|
| Synonym | More Synonyms |
| Description | Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity; demonstrates subgenomic antiviral activity against GT1b and GT1a with EC50 of 11 and 23 nM in cell-based replicon assays; shows weak or no inhibition in specificity assays that include poliovirus RdRp, mammalian DdRp II, and DNA polymerase α, β, and γ; displays good antiviral potency and tolerability in early clinical trials of short-term treatment either as a single agent or in combination with pegylated IFN-α2a/ribavirin in HCV GT1 patients. HCV Infection Phase 3 Clinical |
|---|---|
| References | References 1. Zeuzem S, et al. Gastroenterology. 2011 Dec;141(6):2047-55; quiz e14. 2. Zeuzem S, et al. Antivir Ther. 2013;18(8):1015-9. 3. Larrey D, et al. Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. 4. LaPlante SR, et al. J Med Chem. 2014 Mar 13;57(5):1845-54. View Related Products by Target HCV HCV Infection |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 851.4±65.0 °C at 760 mmHg |
| Molecular Formula | C34H33BrN6O3 |
| Molecular Weight | 653.568 |
| Flash Point | 468.7±34.3 °C |
| Exact Mass | 652.179749 |
| LogP | 6.15 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.736 |
| InChIKey | BMAIGAHXAJEULY-UKTHLTGXSA-N |
| SMILES | Cn1c(C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Br)cn5)n(C)c4c3)CCC2)nc2ccc(C=CC(=O)O)cc21 |
| 2-Propenoic acid, 3-[2-[1-[[[2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- |
| 58BU988K90 |
| BI 207127 |
| (2E)-3-{2-[1-({[2-(5-Bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl]carbonyl}amino)cyclobutyl]-1-methyl-1H-benzimidazol-6-yl}acrylic acid |
| Deleobuvir |